Tirzepatide has emerged as a groundbreaking treatment for type 2 diabetes, offering promising results. However, the expense of this innovative drug and its supply have become key concerns for patients and healthcare practitioners. While tirzepatide has been authorized by regulatory agencies, its expensive nature presents a significant barrier to m